WallStSmart

Centessa Pharmaceuticals PLC ADR (CNTA)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 3943% more annual revenue ($606.42M vs $15.00M). CNTA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

CNTA

Avoid

24

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -1.30

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNTA0 strengths · Avg: 0/10

No standout strengths identified

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CNTA4 concerns · Avg: 3.8/10
Price/BookValuation
12.6x4/10

Trading at 12.6x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CNTA

CNTA has a balanced fundamental profile.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CNTA

The primary concerns for CNTA are Price/Book, Revenue Growth, EPS Growth.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CNTA profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

CNTA carries more volatility with a beta of 1.55 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

CNTA generates stronger free cash flow (-59M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Centessa Pharmaceuticals PLC ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?